2023
Cardiology Encounters for Underrepresented Racial and Ethnic Groups with Human Immunodeficiency Virus and Borderline Cardiovascular Disease Risk
Bloomfield G, Hill C, Chiswell K, Cooper L, Gray S, Longenecker C, Louzao D, Marsolo K, Meissner E, Morse C, Muiruri C, Thomas K, Velazquez E, Vicini J, Pettit A, Sanders G, Okeke N. Cardiology Encounters for Underrepresented Racial and Ethnic Groups with Human Immunodeficiency Virus and Borderline Cardiovascular Disease Risk. Journal Of Racial And Ethnic Health Disparities 2023, 11: 1509-1519. PMID: 37160576, PMCID: PMC10632543, DOI: 10.1007/s40615-023-01627-0.Peer-Reviewed Original ResearchBody mass indexCVD riskCardiovascular diseaseCVD risk factor managementCox proportional hazards regressionHigher body mass indexUrban residenceRisk factor managementCardiovascular disease riskHuman immunodeficiency virusProportional hazards regressionAssociation of patientHigh-risk individualsAcademic medical centerAmbulatory visitsMedian ageMass indexProvider factorsAtrial fibrillationHazards regressionImmunodeficiency virusResultsA totalFactor managementInsurance typeMedical Center
2010
Evidence for the efficacy of ARBs across the cardiovascular continuum
Gupta M, Honos GN, Velazquez EJ, Chung N, Oigman W, Maggioni AP. Evidence for the efficacy of ARBs across the cardiovascular continuum. Current Medical Research And Opinion 2010, 26: 1203-1218. PMID: 20302552, DOI: 10.1185/03007991003712159.Peer-Reviewed Original ResearchConceptsAngiotensin II receptor blockersPatient populationARB classCV continuumPre-specified risk factorsMajor CV outcomesII receptor blockersPrimary prevention studiesCardiovascular disease riskAdditional patient populationsDifferent patient populationsNumerous patient populationsMajor literature databasesCardiovascular continuumCV eventsCV morbidityCV outcomesReceptor blockersSecondary preventionACE inhibitorsAntihypertensive agentsOngoing trialsPrevention StudyRisk factorsDisease risk